mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.
TORONTO, Sept. 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
On August 31, 2021, the Company anno... Read More...
TORONTO, Aug. 31, 2021 - Aion Therapeutic Inc. (CSE: AION)Â ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed dea... Read More...
TORONTO, July 14, 2021 - Aion Therapeutic Inc. (CSE: AION)Â ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, takin... Read More...
LONDON and TORONTO, May 18, 2021 - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased ... Read More...
TORONTO, April 21, 2021 -Â Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ br... Read More...
TORONTO, April 12, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") today announced that it has retained KCSA Strategic Communications ("KCSA"), a leading New York City-based communications firm.
KCSA will work with management to create a comprehensive, strategic communications program to lead the Company's p... Read More...
TORONTO, March 11, 2021 - Aion Therapeutic Inc. (CSE: AION)Â ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer,... Read More...
Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The A... Read More...
Neuroscientist, Healthcare Technology Entrepreneur to Lead Aion Through Important Next PhaseToronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. Thompson, Ph.D. as its new president.Dr. Thompson is an acc... Read More...
Toronto, Ontario--(Newsfile Corp. - September 18, 2020) - Â Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 9,090,907 units ("Units") at a price of $0.055 per Unit for gross proceeds of approximately $500,000 (the "Offerin... Read More...
Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion TherapeuticToronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas... Read More...
Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that it will be changing its name to "Aion Therapeutic Inc." The Company's new stock symbol on the Canadian Securities Exchange will be "AION", and the name change will be effective on or about August... Read More...
Toronto, Ontario--(Newsfile Corp. - August 19, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to provide a Board of Directors ("Board of Directors" or the "Board") update following the recent election of the Company's new Board of Directors which includes the appointment of a new Executive Chair, Executiv... Read More...
Toronto, Ontario--(Newsfile Corp. - August 10, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce the results from the Company's annual and special meeting of shareholders held on Friday, August 7, 2020 (the "Meeting").Shareholders holding a total of 34,335,039 common shares of the Company were re... Read More...
Toronto, Ontario--(Newsfile Corp. - August 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that the Company has closed its previously announced non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for g... Read More...
Toronto, Ontario--(Newsfile Corp. - July 20, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has closed a second tranche of its previously announced non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per... Read More...
Toronto, Ontario--(Newsfile Corp. - July 8, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") today provided a corporate update on its previously announced acquisition of 1196691 B.C. Ltd. d/b/a "PCAI Pharma" ("PCAI") and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited ("AI Pharma").About PCAIPCAI is a T... Read More...
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it completed its previously announced acquisition of AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a company engaged in the research and development of cannabis (cannabinoids) and mushrooms (psilocin)... Read More...
Toronto, Ontario--(Newsfile Corp. - June 26, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it has agreed to acquire 100% of the shares (the "Acquisition") of 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (the "Parent") the parent company that holds 100% of the shares of AI Pharmaceuticals Jamaica Limit... Read More...
Toronto, Ontario--(Newsfile Corp. - June 16, 2020) - Â Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it proposes to complete a non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for gross proceeds of up to $1,000... Read More...
Toronto, Ontario--(Newsfile Corp. - June 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has rescheduled its next annual and special meeting of shareholders (the "Annual Meeting") to be held on August 7, 2020.Management had initially scheduled its Annual Meeting to be held on July ... Read More...
Toronto, Ontario--(Newsfile Corp. - May 26, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announced that both of the Company's Vitalis Q-180 Series extraction systems (the "Extraction Systems") have been commissioned for operation and all requisite approvals from the federal and provincial regulators ... Read More...
Toronto, Ontario--(Newsfile Corp. - April 21, 2020) - Â Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has entered into an equipment lease (the "Equipment Lease") and a joint-venture agreement (the "JV Agreement") with 2623942 Ontario Limited (the "Licensed Producer"). Furthermore, the Compan... Read More...
Toronto, Ontario--(Newsfile Corp. - January 20, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company's board of directors has accepted the resignation of Ernie Eves as a director of the Company and has appointed Graham Simmonds, Tyler Devenyi and Larry Horwitz to serve as directors of the ... Read More...
Toronto, Ontario--(Newsfile Corp. - September 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announces that it has entered into a debt settlement agreement with an arm's length creditor. The agreement reduces the Company's liabilities by $750,000 and improves the Company's financial position with respect to both... Read More...
Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company"), a cannabinoid-focused processing and extraction company, is pleased to announce that, further to its press release of September 4, 2019, it has been advised by the Canadian Securities Exchange that trading in its common ... Read More...
Toronto, Ontario--(Newsfile Corp. - September 4, 2019) - Â Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company) wishes to announce that its letter of intent with Anahit International Corp. ("Anahit") as previously announced on May 16, 2019 (the "LOI") has been terminated. Pursuant to the LOI, Osoyoos and Anahit were to complete a b... Read More...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, July 26, 2019 -- Leo Acquisitions Corp. (LEQ-H.V) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and ... Read More...
Toronto, Ontario--(Newsfile Corp. - May 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) (the "Company") announces that the Board of Directors has secured extended and improved terms of a loan note initially payable on March 15, 2020, to a founder and former Director of the Company.The principal amount of one million dollars ($1,000,000 CAD),... Read More...
Toronto, Ontario--(Newsfile Corp. - May 16, 2019) - Osoyoos Cannabis Inc. (CSE:OSO) ("Osoyoos" or the "Company") and Anahit International Corp. ("Anahit" or "Target") are pleased to announce today that they have entered into a non-binding letter of intent ("LOI"), which subject to, among other things, due diligence of each party, the nego... Read More...
